GW Pharmaceuticals PLC is a
biopharmaceutical company focused on the development and commercialization of
novel therapeutics from its proprietary cannabinoid product platform.
Currently, the company’s primary product offering is Sativex®, which is
approved for the treatment of spasticity related to multiple sclerosis in 27
countries outside of the United States. To increase market share, the company
has entered into licensing agreements for Sativex® with major industry players,
including Bayer Healthcare in the UK and Canada and Almirall in Europe and Mexico,
providing a platform for enhanced returns moving forward. In addition to
approval for spasticity treatment, Sativex® is also in Phase III clinical
development for the treatment of cancer pain, which is the lead indication for
the US market.
Since 2007, GW has established a
world leading position in cannabinoid science development through a global
cannabinoid research agreement with Japanese pharmaceutical giant Otsuka. Under
this collaboration, the company is primarily researching novel cannabinoid
treatments for Central Nervous System disorders and oncology.
In addition to Sativex®, GW is
currently developing Epidiolex®, an investigational drug designed to treat one
of the most common neurological disorders in children, pediatric epilepsy. When
completed, Epidiolex® should become the leading treatment for the disorder,
providing a better solution to an underserved market of nearly 250,000 patients
throughout the United States and Europe.
In an effort to prepare for
future growth, GW recently announced the relocation of its Chief Executive
Officer to its new United States operations center. A local presence within the
US market could provide GW with the opportunity to realize substantial growth
as the company’s products approach their final stages of clinical development
in the United States. Likewise, the company is continuing to expand its UK
manufacturing and R&D operations in preparation for future
commercialization of its most advanced drug candidates.
“As Epidiolex® nears its final
stages of clinical development and as GW prepares for future U.S. launch, the
time is right to start building our in-house U.S. commercial infrastructure,”
stated Dr. Geoffrey Guy, Chairman of GW.
With continuing progress towards
pivotal Phase III advanced cancer pain results, an impending launch of Sativex®
in the US and the advancement of its proprietary pipeline of cannabinoid orphan
drug opportunities, GW is in a strong position to provide improved shareholder
returns in the coming months. Moving forward, it’s an opportune time for
prospective shareholders to consider investing in this expanding company.
For more information, visit
www.gwpharm.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
